230 related articles for article (PubMed ID: 19070991)
61. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study.
Haro JM; Novick D; Bertsch J; Karagianis J; Dossenbach M; Jones PB
Br J Psychiatry; 2011 Sep; 199(3):194-201. PubMed ID: 21881098
[TBL] [Abstract][Full Text] [Related]
62. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia.
Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Heuser I; Maier W; Klosterkötter J; Falkai P; Schlösser R; Schmitt A; Riedel M; Klingberg S; Köpcke W; Ohmann C; Möller HJ
Schizophr Res; 2014 Feb; 152(2-3):478-86. PubMed ID: 23643327
[TBL] [Abstract][Full Text] [Related]
63. The concurrent and predictive validity of symptomatic remission criteria in first-episode schizophrenia.
Chang WC; Chan TC; Chen ES; Hui CL; Wong GH; Chan SK; Lee EH; Chen EY
Schizophr Res; 2013 Jan; 143(1):107-15. PubMed ID: 23151398
[TBL] [Abstract][Full Text] [Related]
64. Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study.
Haro JM; Altamura C; Corral R; Elkis H; Evans J; Krebs MO; Zink M; Malla A; Méndez JI; Bernasconi C; Lalonde J; Nordstroem AL
Psychiatry Res; 2018 Sep; 267():56-62. PubMed ID: 29883861
[TBL] [Abstract][Full Text] [Related]
65. Attaining and sustaining remission of predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Jan; 143(1):60-4. PubMed ID: 23218563
[TBL] [Abstract][Full Text] [Related]
66. Prospective memory predicts medication management ability and correlates with non-adherence to medications in individuals with clinically stable schizophrenia.
Lam JW; Lui SS; Wang Y; Chan RC; Cheung EF
Schizophr Res; 2013 Jul; 147(2-3):293-300. PubMed ID: 23631929
[TBL] [Abstract][Full Text] [Related]
67. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.
Ventura J; Subotnik KL; Gitlin MJ; Gretchen-Doorly D; Ered A; Villa KF; Hellemann GS; Nuechterlein KH
Schizophr Res; 2015 Feb; 161(2-3):407-13. PubMed ID: 25499044
[TBL] [Abstract][Full Text] [Related]
68. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder.
Hofer A; Rettenbacher MA; Widschwendter CG; Kemmler G; Hummer M; Fleischhacker WW
Eur Arch Psychiatry Clin Neurosci; 2006 Jun; 256(4):246-55. PubMed ID: 16311896
[TBL] [Abstract][Full Text] [Related]
69. Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years.
Lambert M; Schimmelmann BG; Schacht A; Karow A; Wagner T; Wehmeier PM; Huber CG; Hundemer HP; Dittmann RW; Naber D
Schizophr Res; 2009 Feb; 107(2-3):165-72. PubMed ID: 18842393
[TBL] [Abstract][Full Text] [Related]
70. Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting.
Chiliza B; Ojagbemi A; Esan O; Asmal L; Oosthuizen P; Kidd M; Gureje O; Emsley R
Early Interv Psychiatry; 2016 Feb; 10(1):54-62. PubMed ID: 24690088
[TBL] [Abstract][Full Text] [Related]
71. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®).
Acosta FJ; Ramallo-Fariña Y; Bosch E; Mayans T; Rodríguez CJ; Caravaca A
Schizophr Res; 2013 May; 146(1-3):196-200. PubMed ID: 23474024
[TBL] [Abstract][Full Text] [Related]
72. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.
Swanson JW; Swartz MS; Elbogen EB
Schizophr Bull; 2004; 30(1):3-20. PubMed ID: 15176758
[TBL] [Abstract][Full Text] [Related]
73. Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia.
Højlund M; Elliott AF; Madsen NJ; Viuff AG; Munk-Jørgensen P; Hjorth P
Nord J Psychiatry; 2017 Nov; 71(8):598-604. PubMed ID: 28836471
[TBL] [Abstract][Full Text] [Related]
74. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.
Mohamed S; Rosenheck R; McEvoy J; Swartz M; Stroup S; Lieberman JA
Schizophr Bull; 2009 Mar; 35(2):336-46. PubMed ID: 18586692
[TBL] [Abstract][Full Text] [Related]
75. Remission as perceived by people with schizophrenia, family members and psychiatrists.
Karow A; Naber D; Lambert M; Moritz S;
Eur Psychiatry; 2012 Aug; 27(6):426-31. PubMed ID: 21571506
[TBL] [Abstract][Full Text] [Related]
76. The influence of adherence to antipsychotics medication on the quality of life among patients with schizophrenia in Indonesia.
Endriyani L; Chien CH; Huang XY; Chieh-Yu L
Perspect Psychiatr Care; 2019 Apr; 55(2):147-152. PubMed ID: 29578605
[TBL] [Abstract][Full Text] [Related]
77. The effect of baseline antipsychotic status on the 12-month outcome in initially stabilized patients with schizophrenia.
Fountoulakis KN; Panagiotidis P; Nimatoudis I
Hum Psychopharmacol; 2019 Sep; 34(5):e2712. PubMed ID: 31486169
[TBL] [Abstract][Full Text] [Related]
78. Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.
Vassileva I; Milanova V; Asan T
Community Ment Health J; 2014 Oct; 50(7):854-61. PubMed ID: 24452824
[TBL] [Abstract][Full Text] [Related]
79. Remission in schizophrenia: applying recent consensus criteria to refine the concept.
Lasser RA; Nasrallah H; Helldin L; Peuskens J; Kane J; Docherty J; Tronco AT
Schizophr Res; 2007 Nov; 96(1-3):223-31. PubMed ID: 17765480
[TBL] [Abstract][Full Text] [Related]
80. Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients.
Bitter I; Basson BR; Dossenbach MR
Int Clin Psychopharmacol; 2005 Jan; 20(1):19-21. PubMed ID: 15602111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
